Patients with PNPLA3 I148M variant represent a subset of NAFLD patients at higher risk for liver damage, characterized by a particularly increased oxidative stress, which seems to play a key role in triggering the process of fibrosis. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.